secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2025-01-08T23:59:59+00:00
Accession:  0001159036-25-000003
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme raises 2025 guidance: rev $1.15-1.225B, adj EBITDA $755-805M, $250M ASR
--------------------------------------------------------------------------------

- Raises 2025 total revenue guidance to $1,150-$1,225M, representing 16-23% YoY growth from 2024 midpoint.
- Raises 2025 adjusted EBITDA guidance to $755-$805M (24-32% YoY) and non-GAAP diluted EPS to $4.95-$5.35 (21-30% YoY).
- Announces new $250M accelerated share repurchase (ASR) under existing $750M share repurchase program.
- Reiterates 2024 preliminary unaudited guidance: revenue $970-$1,020M, adjusted EBITDA $595-$625M, non-GAAP EPS $4.00-$4.20.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000115903625000003/0001159036-25-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000115903625000003/halo-20250108.htm
  HTML page:      https://secwatch.observer/filing/0001159036-25-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer